AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Aquestive Therapeutics, Inc.
Video analysis: AQST
All videosNo video analysis for this stock yet. Request one from our team.
News: AQST
8,069,373 Shares in Aquestive Therapeutics, Inc. $AQST Acquired by BlackRock Inc.
BlackRock Inc. bought a new position in Aquestive Therapeutics, Inc. (NASDAQ: AQST) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 8,069,373 shares of the company's stock, valued at approximately $33,569,000. BlackRock Inc. owned 6.43% of Aquestive Therapeutics as of its most recent
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in September 2026 as follows:
AWM Investment Company Inc. Takes $1.98 Million Position in Aquestive Therapeutics, Inc. $AQST
AWM Investment Company Inc. purchased a new position in Aquestive Therapeutics, Inc. (NASDAQ: AQST) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 475,400 shares of the company's stock, valued at approximately $1,978,000. AWM Investment Company Inc. owned
Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript
Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript
Aquestive Therapeutics Q2 Earnings Call Highlights
Aquestive Therapeutics NASDAQ: AQST said it plans to resubmit its new drug application for Anaphylm, its epinephrine sublingual film candidate for type 1 allergic reactions including anaphylaxis, before the end of the third quarter after completing studies requested by the U.S. Food and Drug Administration.
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.14 per share a year ago.
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2026, and provided a strategic business update.
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study
Aquestive Therapeutics Inc. (NASDAQ:AQST) announced positive findings from human factors and pharmacokinetic validation studies for its Anaphylm (dibutepinephrine) sublingual film.
